JPRN-UMIN000053168招募中Unknown
The efficacy and safety of the pemafibrate in subjects with dyslipidemia and severely decreased renal function; a prospective observational study - Pema-severe CKD study
Kushiro Red Cross Hospital0 个研究点目标入组 60 人开始时间: 2023年12月25日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Subjects with serious liver complications 2) Subjects who are deemed to be unsuitable by the investigator
研究者
相似试验
招募中
不适用
Safety and efficacy of pemafibrate (Parmodia) for patients having dyslipidemia and non-alcoholic fatty liver disease (NAFLD)JPRN-UMIN000035248Shinshu University School of Medicine20
尚未招募
不适用
Clinical benefit of pemafibrate in patients with primary biliary cholangitis (PBC) with dyslipidemiaprimary biliary cholangitisJPRN-UMIN000039350Shinshu University Faculty of Medicine, Department of Gastroenterology60
招募中
2 期
Randomized controlled trial of pemafibrate and fenofibrate for NAFLD with hypertriglyceridemiaJPRN-jRCTs031200280Iwaki Michihiro360
招募中
3 期
Study of efficacy and safety of suranjafel in patients with rheumatoid arthritisRheumatoid Arthritis.Rheumatoid arthritis, unspecifiedM06.9IRCT20211214053400N1Ghoum University of Medical Sciences88
已完成
不适用
Effect of addition of pemafibrate and double dose of statin on small dense LDL cholesterol in statin-treated patients with type 2 diabetes and hypertriglyceridemia: A comparative Study.HypertriglyceridemiaJPRN-jRCTs031190232Mori Yusaku102